Algernon Pharmaceuticals Inc C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc

Bullboard Posts

Comment by DigitalSpurson Apr 17, 2020 11:27am

79 Views

Post# 30921936

RE:The Gillead Factor

You are right about the spotlight, but the spotlight is just that

Look at this list of migraine treatments (I know it isn't Covid, but again, one drug will not be the answer for it all - we humans don't work like that haha)

https://www.webmd.com/migraines-headaches/migraine-treatment#1

The matter of fact is that AGN is working hard on getting their trials done on a drug that already has FDA approval and are working with a very reputable chemist to synthesize

Bullboard Posts

How to interpret movements in the price of gold